Evaluation of cytokeratin 19 serum fragments (CYFRA 21-1) in patients with lung cancer: Results of a multicenter trial

E. Bombardieri, E. Seregni, A. Bogni, S. Ardit, S. Belloli, A. Busetto, B. Caniello, M. Castelli, A. Cianetti, M. Correale, G. De Angelis, G. M. Gandolfo, M. gion, V. Macchia, R. Mione, F. Navaglia, M. Onetto, M. Paganbuzzi, F. Pecchio

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Recently, a new immunometric assay (Cyfra 21-1) was developed to measure serum concentrations of a soluble fragment of cytokeratin subunit 19. With this method, supplied by Boehringer Mannheim (EIA Test Cyfra 21-1), an Italian multicenter trial was performed in patients with lung cancer. Cyfra 21-1 serum levels were determined in 568 normal subjects (blood donors), 607 patients with non-malignant diseases (491 respiratory diseases) and 730 patients with malignancies. In the latter group 584 had lung cancer. All these 584 patients had pathologically confirmed disease; 314 were epidermoid tumors, 166 adenocarcinomas, 88 small cell cancers and 16 large cell cancers. In the 568 healthy blood donors the mean Cyfra 21-1 value was 0.91 ng/ml (SD 0.47 ng/ml; range 0.05-2.90 ng/ml). A threshold of 1.9 ng/ml was chosen as the upper limit of normality. High levels of Cyfra 21-1 were observed in patients with chronic hepatitis (positivity rate: 17/51-33.3%) and with pancreatitis (positivity rate 5/16-31.3%). In 114 out of 491 (23.2%) patients with respiratory diseases Cyfra 21-1 showed values greater than 1.9 ng/ml. The overall sensitivity (all stages) of Cyfra 21-1 in lung cancer was 65.6% (383/584). When the histology was considered the highest positivity rates were found in patients with sguamous cell tumors (226/314; 72%) followed by adenocarcinomas (105/166; 63%). In patients with SCLC the global sensitivity was 52.3% (46/88). Higher sensitivity of Cyfra 21-1 was observed from stage I to stage IV (53.9% vs 85.7%; Chi square: p <0.01). When comparing patients in whom curative resections were possible (up to stage IIIa) with patients suffering from inoperable tumors, a significant difference in Cyfra 21-1 positivies was found (59% vs 81.5%; Chi square p <0.01).

Original languageEnglish
Pages (from-to)89-95
Number of pages7
JournalInternational Journal of Biological Markers
Volume9
Issue number2
Publication statusPublished - 1994

Fingerprint

Keratin-19
Multicenter Studies
Tumors
Lung Neoplasms
Pulmonary diseases
Blood
Serum
Histology
Keratins
Assays
Neoplasms
Blood Donors
Adenocarcinoma
antigen CYFRA21.1
Chronic Hepatitis
Pancreatitis

Keywords

  • Cyfra 21-1
  • cytokeratins
  • lung cancer
  • tumor markers

ASJC Scopus subject areas

  • Immunology
  • Biochemistry

Cite this

Evaluation of cytokeratin 19 serum fragments (CYFRA 21-1) in patients with lung cancer : Results of a multicenter trial. / Bombardieri, E.; Seregni, E.; Bogni, A.; Ardit, S.; Belloli, S.; Busetto, A.; Caniello, B.; Castelli, M.; Cianetti, A.; Correale, M.; De Angelis, G.; Gandolfo, G. M.; gion, M.; Macchia, V.; Mione, R.; Navaglia, F.; Onetto, M.; Paganbuzzi, M.; Pecchio, F.

In: International Journal of Biological Markers, Vol. 9, No. 2, 1994, p. 89-95.

Research output: Contribution to journalArticle

Bombardieri, E, Seregni, E, Bogni, A, Ardit, S, Belloli, S, Busetto, A, Caniello, B, Castelli, M, Cianetti, A, Correale, M, De Angelis, G, Gandolfo, GM, gion, M, Macchia, V, Mione, R, Navaglia, F, Onetto, M, Paganbuzzi, M & Pecchio, F 1994, 'Evaluation of cytokeratin 19 serum fragments (CYFRA 21-1) in patients with lung cancer: Results of a multicenter trial', International Journal of Biological Markers, vol. 9, no. 2, pp. 89-95.
Bombardieri, E. ; Seregni, E. ; Bogni, A. ; Ardit, S. ; Belloli, S. ; Busetto, A. ; Caniello, B. ; Castelli, M. ; Cianetti, A. ; Correale, M. ; De Angelis, G. ; Gandolfo, G. M. ; gion, M. ; Macchia, V. ; Mione, R. ; Navaglia, F. ; Onetto, M. ; Paganbuzzi, M. ; Pecchio, F. / Evaluation of cytokeratin 19 serum fragments (CYFRA 21-1) in patients with lung cancer : Results of a multicenter trial. In: International Journal of Biological Markers. 1994 ; Vol. 9, No. 2. pp. 89-95.
@article{ca6b70d1507d4b6f8ba86b976247f43b,
title = "Evaluation of cytokeratin 19 serum fragments (CYFRA 21-1) in patients with lung cancer: Results of a multicenter trial",
abstract = "Recently, a new immunometric assay (Cyfra 21-1) was developed to measure serum concentrations of a soluble fragment of cytokeratin subunit 19. With this method, supplied by Boehringer Mannheim (EIA Test Cyfra 21-1), an Italian multicenter trial was performed in patients with lung cancer. Cyfra 21-1 serum levels were determined in 568 normal subjects (blood donors), 607 patients with non-malignant diseases (491 respiratory diseases) and 730 patients with malignancies. In the latter group 584 had lung cancer. All these 584 patients had pathologically confirmed disease; 314 were epidermoid tumors, 166 adenocarcinomas, 88 small cell cancers and 16 large cell cancers. In the 568 healthy blood donors the mean Cyfra 21-1 value was 0.91 ng/ml (SD 0.47 ng/ml; range 0.05-2.90 ng/ml). A threshold of 1.9 ng/ml was chosen as the upper limit of normality. High levels of Cyfra 21-1 were observed in patients with chronic hepatitis (positivity rate: 17/51-33.3{\%}) and with pancreatitis (positivity rate 5/16-31.3{\%}). In 114 out of 491 (23.2{\%}) patients with respiratory diseases Cyfra 21-1 showed values greater than 1.9 ng/ml. The overall sensitivity (all stages) of Cyfra 21-1 in lung cancer was 65.6{\%} (383/584). When the histology was considered the highest positivity rates were found in patients with sguamous cell tumors (226/314; 72{\%}) followed by adenocarcinomas (105/166; 63{\%}). In patients with SCLC the global sensitivity was 52.3{\%} (46/88). Higher sensitivity of Cyfra 21-1 was observed from stage I to stage IV (53.9{\%} vs 85.7{\%}; Chi square: p <0.01). When comparing patients in whom curative resections were possible (up to stage IIIa) with patients suffering from inoperable tumors, a significant difference in Cyfra 21-1 positivies was found (59{\%} vs 81.5{\%}; Chi square p <0.01).",
keywords = "Cyfra 21-1, cytokeratins, lung cancer, tumor markers",
author = "E. Bombardieri and E. Seregni and A. Bogni and S. Ardit and S. Belloli and A. Busetto and B. Caniello and M. Castelli and A. Cianetti and M. Correale and {De Angelis}, G. and Gandolfo, {G. M.} and M. gion and V. Macchia and R. Mione and F. Navaglia and M. Onetto and M. Paganbuzzi and F. Pecchio",
year = "1994",
language = "English",
volume = "9",
pages = "89--95",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "2",

}

TY - JOUR

T1 - Evaluation of cytokeratin 19 serum fragments (CYFRA 21-1) in patients with lung cancer

T2 - Results of a multicenter trial

AU - Bombardieri, E.

AU - Seregni, E.

AU - Bogni, A.

AU - Ardit, S.

AU - Belloli, S.

AU - Busetto, A.

AU - Caniello, B.

AU - Castelli, M.

AU - Cianetti, A.

AU - Correale, M.

AU - De Angelis, G.

AU - Gandolfo, G. M.

AU - gion, M.

AU - Macchia, V.

AU - Mione, R.

AU - Navaglia, F.

AU - Onetto, M.

AU - Paganbuzzi, M.

AU - Pecchio, F.

PY - 1994

Y1 - 1994

N2 - Recently, a new immunometric assay (Cyfra 21-1) was developed to measure serum concentrations of a soluble fragment of cytokeratin subunit 19. With this method, supplied by Boehringer Mannheim (EIA Test Cyfra 21-1), an Italian multicenter trial was performed in patients with lung cancer. Cyfra 21-1 serum levels were determined in 568 normal subjects (blood donors), 607 patients with non-malignant diseases (491 respiratory diseases) and 730 patients with malignancies. In the latter group 584 had lung cancer. All these 584 patients had pathologically confirmed disease; 314 were epidermoid tumors, 166 adenocarcinomas, 88 small cell cancers and 16 large cell cancers. In the 568 healthy blood donors the mean Cyfra 21-1 value was 0.91 ng/ml (SD 0.47 ng/ml; range 0.05-2.90 ng/ml). A threshold of 1.9 ng/ml was chosen as the upper limit of normality. High levels of Cyfra 21-1 were observed in patients with chronic hepatitis (positivity rate: 17/51-33.3%) and with pancreatitis (positivity rate 5/16-31.3%). In 114 out of 491 (23.2%) patients with respiratory diseases Cyfra 21-1 showed values greater than 1.9 ng/ml. The overall sensitivity (all stages) of Cyfra 21-1 in lung cancer was 65.6% (383/584). When the histology was considered the highest positivity rates were found in patients with sguamous cell tumors (226/314; 72%) followed by adenocarcinomas (105/166; 63%). In patients with SCLC the global sensitivity was 52.3% (46/88). Higher sensitivity of Cyfra 21-1 was observed from stage I to stage IV (53.9% vs 85.7%; Chi square: p <0.01). When comparing patients in whom curative resections were possible (up to stage IIIa) with patients suffering from inoperable tumors, a significant difference in Cyfra 21-1 positivies was found (59% vs 81.5%; Chi square p <0.01).

AB - Recently, a new immunometric assay (Cyfra 21-1) was developed to measure serum concentrations of a soluble fragment of cytokeratin subunit 19. With this method, supplied by Boehringer Mannheim (EIA Test Cyfra 21-1), an Italian multicenter trial was performed in patients with lung cancer. Cyfra 21-1 serum levels were determined in 568 normal subjects (blood donors), 607 patients with non-malignant diseases (491 respiratory diseases) and 730 patients with malignancies. In the latter group 584 had lung cancer. All these 584 patients had pathologically confirmed disease; 314 were epidermoid tumors, 166 adenocarcinomas, 88 small cell cancers and 16 large cell cancers. In the 568 healthy blood donors the mean Cyfra 21-1 value was 0.91 ng/ml (SD 0.47 ng/ml; range 0.05-2.90 ng/ml). A threshold of 1.9 ng/ml was chosen as the upper limit of normality. High levels of Cyfra 21-1 were observed in patients with chronic hepatitis (positivity rate: 17/51-33.3%) and with pancreatitis (positivity rate 5/16-31.3%). In 114 out of 491 (23.2%) patients with respiratory diseases Cyfra 21-1 showed values greater than 1.9 ng/ml. The overall sensitivity (all stages) of Cyfra 21-1 in lung cancer was 65.6% (383/584). When the histology was considered the highest positivity rates were found in patients with sguamous cell tumors (226/314; 72%) followed by adenocarcinomas (105/166; 63%). In patients with SCLC the global sensitivity was 52.3% (46/88). Higher sensitivity of Cyfra 21-1 was observed from stage I to stage IV (53.9% vs 85.7%; Chi square: p <0.01). When comparing patients in whom curative resections were possible (up to stage IIIa) with patients suffering from inoperable tumors, a significant difference in Cyfra 21-1 positivies was found (59% vs 81.5%; Chi square p <0.01).

KW - Cyfra 21-1

KW - cytokeratins

KW - lung cancer

KW - tumor markers

UR - http://www.scopus.com/inward/record.url?scp=0028305555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028305555&partnerID=8YFLogxK

M3 - Article

C2 - 7523547

AN - SCOPUS:0028305555

VL - 9

SP - 89

EP - 95

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 2

ER -